Adicet Bio, Inc. Common Stock ACET
i
Market datapartial · fetched 2026-11-04T07:31:33.876Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:00.835141478Z
FundamentalsAlpha Vantage · unavailable
Adicet Bio, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.67 | 326.5% | 56.9% | |||
| 25Δ | 3.14 | 309.8% | 50.9% | |||
| 30Δ | 3.62 | 293.2% | 44.9% | |||
| 35Δ | 4.09 | 276.6% | 38.9% | |||
| 40Δ | 4.56 | 259.9% | 32.9% | |||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | ||||||
| 60Δ | ||||||
| 65Δ | ||||||
| 70Δ | 5.36 | 385.3% | 119.3% | |||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.67
- IV
- 326.5%
- B/E move
- 56.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.14
- IV
- 309.8%
- B/E move
- 50.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.62
- IV
- 293.2%
- B/E move
- 44.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.09
- IV
- 276.6%
- B/E move
- 38.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.56
- IV
- 259.9%
- B/E move
- 32.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 5.36
- IV
- 385.3%
- B/E move
- 119.3%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 258.08% | |
| 165.59% | |
| 184.86% | |
| 167.61% | |
| 181.88% | |
| 249.35% | |
| 266.48% | |
| 161.86% | |
| 169.79% | |
| 165.17% | |
| 212.73% |
Biotechnology
ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and…
More →ACIU
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative…
More →ACOG
Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on…
More →ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with…
More →ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and…
More →AGEN
Description unavailable
More →